NOVABAY PHARMACEUTICALS INC (NBY) Stock Income Statement
NYSEARCA:NBY - NYSE Arca - US66987P4090 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.78M | 14.73M | 14.40M | 8.42M | 9.93M | |||
| Cost Of Goods | 3.30M | 6.83M | 6.62M | 2.48M | 3.97M | |||
| Gross Profit | 6.48M | 7.89M | 7.78M | 5.95M | 5.96M | |||
| Operating Expenses | 11.46M | 12.90M | 15.46M | 12.80M | 12.39M | |||
| Research and Development | 42.00K | 68.00K | 170.00K | 40.00K | 290.00K | |||
| Selling, General, and Administrative Expenses | 11.41M | 12.83M | 15.29M | 12.76M | 12.11M | |||
| Operating Income | -4.97M | -5.00M | -7.68M | -6.86M | -6.43M | |||
| Interest Income/Expense | 96.00K | 20.00K | 4.09M | 4.62M | -5.21M | |||
| Other Income/Expense | -1.45M | -2.06M | -280.00K | -1.58M | 610.00K | |||
| Non Recurring Items | -878.00K | -2.59M | -6.74M | -2.00M | N/A | |||
| Income Before Taxes | -7.21M | -9.64M | -10.61M | -5.82M | -11.03M | |||
| Income Tax | N/A | N/A | 0.00 | 0.00 | 10.00K | |||
| Net Income | -8.61M | -16.70M | -16.27M | -6.56M | -11.04M | |||
| EBITDA | -4.93M | -4.80M | -7.20M | -6.74M | -6.38M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.53 | -138.65 | -10.10 | -5.26 | -11.02 | |||
| Non GAAP EPS | N/A | -111.65 | -260.05 | -183.75 | -404.25 | |||
| Statistics | ||||||||
| Gross Profit Margin | 66.26% | 53.61% | 54.03% | 70.67% | 60.02% | |||
| Profit Margin | -88.01% | -113.38% | -112.99% | -77.91% | -111.18% | |||
| Operating Profit Margin | -50.85% | -33.97% | -53.33% | -81.47% | -64.75% | |||
All data in USD